GSK vs LLY vs AZN vs NVS

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 4. 1% for GSK plc (GSK). GSK plc (GSK) offers the better valuation at 6. 7x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GSK plc (GSK) is the cheapest at 6.

7x versus Eli Lilly and Company at 41. 3x. On forward P/E, GSK plc is actually cheaper at 10. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: GSK plc wins at 0. 73x versus Novartis AG's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +399.

3%, compared to +52. 6% for GSK plc (GSK). Over 10 years, the gap is even starker: LLY returned +1203% versus GSK's +62. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus Eli Lilly and Company's 0. 65β — meaning LLY is approximately 56% more volatile than NVS relative to the S&P 500. On balance sheet safety, AstraZeneca PLC (AZN) carries a lower debt/equity ratio of 61% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 4. 1% for GSK plc (GSK). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to 22. 5% for Novartis AG. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 17. 5% for AstraZeneca PLC — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 23. 4% for AZN. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, GSK plc (GSK) is the more undervalued stock at a PEG of 0. 73x versus Novartis AG's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, GSK plc (GSK) trades at 10. 4x forward P/E versus 26. 3x for Eli Lilly and Company — 15. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 33. 0% to $1261. 11.

All stocks in this comparison pay dividends.

GSK plc (GSK) offers the highest yield at 6. 6%, versus 0. 6% for Eli Lilly and Company (LLY).

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Both have compounded well over 10 years (LLY: +1203%, AZN: +269. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GSK is a mid-cap deep-value stock; LLY is a large-cap high-growth stock; AZN is a large-cap quality compounder stock; NVS is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.